Eckert & Ziegler BEBIG will install the latest generation MultiSource® in the leading private medical hospital in India.
(Thomson Reuters ONE) -
Seneffe, Belgium, July 5, 2011, Eckert & Ziegler BEBIG (NYSE Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB), a global leader in brachytherapy,
announced today that it will install the latest generation MultiSource® Cobalt-
60 HDR afterloader at the St. John's Medical College & Hospital in Bangalore,
India, which is generally regarded as being the foremost private medical
hospital in India. Thenew version of the treatmfent planning module HDRplus(TM)
3.0 will also be installed.
Professor Mazhar H. Shariff, the Hospital's Head of Radiation Oncology,
pronounced that they had chosen a Cobalt-60 HDR system for several reasons: "If
you use the Ir-192 source, you have to replace it every 4 to 6 months and this
is expensive and tedious. Several senior medical physicists interacting with me
assessed that dosimetry is comparable, if not better for Colbal-60 system. We
have also signed the contract for a second Cobalt-60 source, therefore saving on
procedures for replacement and anticipated price rises. Anyway, I will only have
to think about the next source replacement 11 years from now and we may even buy
a new system then. My advice for potential new cancer centers is just to go for
a Cobalt-60 HDR system from Eckert & Ziegler BEBIG. You and your physicist won't
regret it."
St. John's Medical College & Hospital was founded in 1963 by the Catholic
Bishops Conference of India. His Holiness Pope John XXIII agreed to the College
being called after his patron, St. John the Baptist, as a mark of his personal
interest in the project, and of his approval of its aims and ideals. The
cornerstone was blessed by His Holiness Pope Paul VI. St. John's is now listed
as one of the top medical educational institutions in the country. St. John's is
establishing a state-of-the art Cancer Care facility, where the new MultiSource®
will be installed within the department of Radiation Oncology, along with a High
Energy Linear Accelerator.
The MultiSource® HDR afterloader that will be installed belongs to the latest
generation, and was launched earlier this year. It can use either an iridium-
192 or a Cobalt-60 source. Because the half-life of Co-60 is 26 times longer
than that of Ir-192, a Co-60 source has to be replaced only every five years,
reducing costs as well as the problems associated with customs clearance,
maintenance, and disposal. Yet Co-60 delivers equal therapeutic benefit. The
miniaturized high activity Co-60 source is a proprietary product of Eckert &
Ziegler BEBIG. MultiSource® is ideally suited to treat gynecological cancers,
prostate, breast, esophageal and lung cancers, and certain cancers of the head
and neck.
In addition to the MultiSource®, St. John's Hospital will use the new version of
the treatment planning HDRplus(TM) 3.0, an innovative software program for
precise and efficient HDR (High Dose Rate) treatment planning that provides its
users with functions that considerably simplify and speed up their preparation
of the treatment plan.
According to the World Health Organization, cancer rates will continue to rise.
More than 70 percent of all cancer deaths occur in low and middle income
countries. One reason for this grim death toll is the high cost of the equipment
for conventional external beam therapy. Investments for brachytherapy are much
lower. When used with Co-60, the new MultiSource® HDR afterloader reduces
operating costs by up to 80 percent compared to an Ir-192 system.
"Eckert & Ziegler BEBIG is the only company offering a multiple source HDR
afterloader. With our proprietary Co-60 MultiSource® HDR afterloader, we offer a
cost-effective solution in the fight against cancer. We have already installed
over 170 MultiSource® systems worldwide, and more than 20,000 patients were
treated with our systems in 2010," commented Eckert & Ziegler BEBIG's Managing
Director Dr. Edgar Löffler.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device
segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in Germany and
subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
has a worldwide network of distributors and agents to support the international
marketing of its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
on the NYSE Euronext stock exchange since April 1997.
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email:ir(at)bebig.eu
Website:www.bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1528494]
Unternehmensinformation / Kurzprofil:
Datum: 05.07.2011 - 17:41 Uhr
Sprache: Deutsch
News-ID 56149
Anzahl Zeichen: 6015
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 450 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG will install the latest generation MultiSource® in the leading private medical hospital in India."
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
